Literature DB >> 12890591

Current concepts and novel applications of LH activity in ovarian stimulation.

Marco Filicori1, Graciela E Cognigni, Patrizia Pocognoli, Walter Ciampaglia, Silvia Bernardi.   

Abstract

Luteinizing hormone (LH) is a crucial physiological regulator of the human menstrual cycle. LH activity is also contained in many medications used to treat anovulation and to stimulate multiple folliculogenesis for assisted reproduction techniques. However, LH activity had previously been regarded as just a contaminant of follicle-stimulating hormone (FSH)-containing products and deemed potentially detrimental for reproductive function. Novel experimental and clinical evidence now suggests that the administration of pharmacological amounts of LH activity, instead of being harmful, is therapeutically advantageous, particularly in the support and modulation of ovarian folliculogenesis. The aim of this article is to provide an overview of the effects of LH activity administration in ovarian stimulation and to outline novel unconventional gonadotropin regimens that might improve the efficacy, safety and convenience of ovulation induction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890591     DOI: 10.1016/s1043-2760(03)00085-7

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  12 in total

1.  Lutropin alfa: a viewpoint by Giuseppe De Placido, Roberto Clarizia and Carlo Alviggi.

Authors:  Giuseppe De Placido; Roberto Clarizia; Carlo Alviggi
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  LH (Trp8Arg/Ile15Thr), LHR (insLQ) and FSHR (Asn680Ser) polymorphisms genotypic prevalence in women with endometriosis and infertility.

Authors:  Carla Regina Schmitz; Carlos Augusto Bastos de Souza; Vanessa Krebs Genro; Ursula Matte; Emily de Conto; João Sabino Cunha-Filho
Journal:  J Assist Reprod Genet       Date:  2015-05-03       Impact factor: 3.412

Review 3.  The role of luteinizing hormone activity in controlled ovarian stimulation.

Authors:  N Angelopoulos; A Goula; G Tolis
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 4.  Potential regulatory functions of microRNAs in the ovary.

Authors:  Tannaz Toloubeydokhti; Orhan Bukulmez; Nasser Chegini
Journal:  Semin Reprod Med       Date:  2008-10-24       Impact factor: 1.303

5.  Reduced FSH and LH action: implications for medically assisted reproduction.

Authors:  E Bosch; C Alviggi; M Lispi; A Conforti; A C Hanyaloglu; D Chuderland; M Simoni; N Raine-Fenning; P Crépieux; S Kol; V Rochira; T D'Hooghe; P Humaidan
Journal:  Hum Reprod       Date:  2021-05-17       Impact factor: 6.918

6.  Recombinant LH supplementation during IVF cycles with a GnRH-antagonist in estimated poor responders: A cross-matched pilot investigation of the optimal daily dose and timing.

Authors:  Salvatore Gizzo; Alessandra Andrisani; Marco Noventa; Serena Manfè; Alessandra Oliva; Michele Gangemi; Giovanni Battista Nardelli; Guido Ambrosini
Journal:  Mol Med Rep       Date:  2015-06-09       Impact factor: 2.952

7.  Identification and characterization of miRNAs expressed in the bovine ovary.

Authors:  Md Munir Hossain; Nasser Ghanem; Michael Hoelker; Franca Rings; Chirawath Phatsara; Ernst Tholen; Karl Schellander; Dawit Tesfaye
Journal:  BMC Genomics       Date:  2009-09-18       Impact factor: 3.969

Review 8.  Biological versus chronological ovarian age: implications for assisted reproductive technology.

Authors:  Carlo Alviggi; Peter Humaidan; Colin M Howles; Donald Tredway; Stephen G Hillier
Journal:  Reprod Biol Endocrinol       Date:  2009-09-22       Impact factor: 5.211

Review 9.  Overriding follicle selection in controlled ovarian stimulation protocols: quality vs quantity.

Authors:  Richard L Stouffer; Mary B Zelinski-Wooten
Journal:  Reprod Biol Endocrinol       Date:  2004-06-16       Impact factor: 5.211

10.  A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology.

Authors:  Klaus Bühler; Olaf G J Naether; Wilma Bilger
Journal:  Reprod Biol Endocrinol       Date:  2014-01-14       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.